This differentiation can be achieved through variations in dosage form, strength, or combinations, provided there is a documented medical need for such modifications. This pathway allows compounding pharmacies to serve patients with specific requirements not met by the standard FDA-approved medications
A gradual increase in dose allows for lowering the risk of side effects
The market has seen strong traction from newer therapies such as: Eli Lillys Mounjaro (tirzepatide), launched in the UK in February 2024 and made available via the NHS in March 2025 Novo Nordisks Wegovy (semaglutide), introduced in the UK in September 2023 through specialist NHS weight-management services While these newer molecules dominate headlines, liraglutide remains a widely prescribed and proven therapy, and Biocons entry offers a more affordable alternativea key differentiator in public healthcare systems
( 1 ) For men over 30, especially those juggling professional responsibilities, family life, and trying to stay in shape, the dip in energy and mental sharpness can sometimes feel like it came out of nowhere